Global study tracks new lupus drug in everyday use

NCT ID NCT06314282

Summary

This study is observing how well the medication anifrolumab works for people with lupus when used in regular doctor's offices, not just in clinical trials. It will follow 200 patients across several countries for one year to see how their symptoms, skin problems, and quality of life change. The goal is to provide real-world information to help doctors and patients make better treatment decisions.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Research Site

    RECRUITING

    Aktobe, Kazakhstan

  • Research Site

    RECRUITING

    Almaty, Kazakhstan

  • Research Site

    RECRUITING

    Astana, Kazakhstan

  • Research Site

    RECRUITING

    Pavlodar, Kazakhstan

  • Research Site

    RECRUITING

    Semey, Kazakhstan

  • Research Site

    RECRUITING

    Shymkent, Kazakhstan

Conditions

Explore the condition pages connected to this study.